

Producing chimeric recombinant multi-stage vaccine for preventing *Plasmodium falciparum* infection and its community transmission (AdFalcivac)



Domain: Vaccine

About Technology: A recombinant multistage vaccine (AdFalcivac) against *P. falciparum*, produced in *Lactococcus lactis* and a pharmaceutically acceptable carrier for protection against infection in humans, as well as reducing the community transmission

Intended Use: Designed to protect against *Plasmodium falciparum* infection in humans and block community transmission

Advantages:

- Targets two vulnerable parasite stages: pre-erythrocytic and sexual stages of malaria
- Ensures stable, functional chimeric antigens
- Provides protection in humans and helps reduce vector-borne community transmission



IP Status: Filed (Indian Patent application No. - 202411095679)

Development Status: Third Party validation ongoing

Institute(s): ICMR-Regional Medical Research Centre Bhubaneswar (RMRCBB)

Inventor(s): Dr. Susheel K Singh, Dr. Subhash Singh, Dr. Agam P Singh, Dr. Sanghamitra Pati

For Licensing Opportunities contact: patentmitra.hq@icmr.gov.in